Germany-based Boehringer Ingelheim has enrolled the first patient in its Phase II clinical trial BALANCE-CFTM 1 to assess a new potential treatment for cystic fibrosis, a progressive, genetic disease that causes persistent lung infections and limits the ability to breathe over time, it was reported yesterday.
The trial is to investigate how different doses of the compound, an inhaled epithelial sodium channel inhibitor, affect lung function compared to placebo when added to the standard of care in adults and adolescents with cystic fibrosis. The inhaled epithelial sodium channel inhibitor is intended to treat patients with all types of cystic fibrosis mutations. It is inhaled through the Respimat1, which is the company's platform inhaler.
Dr Kay Tetzlaff, head of Medicine, Therapeutic Area Inflammation, Boehringer Ingelheim, said, 'We are pleased to enrol our first patient into this Phase II trial, and we hope our ENaC inhibitor will be proven to help people affected by cystic fibrosis. Boehringer Ingelheim is committed to researching new treatments that address serious unmet needs. We are hopeful that this treatment, along with its delivery method, will make an important difference for patients affected by this debilitating condition.'
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
Aluna Raises USD 15.3m in Series B Funding
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera